The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Subscribe To Our Newsletter & Stay Updated
